Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrUST-HHT: Bevacizumab for Chronic Bleeding and Anemia in HHT
NCT04404881Phase 2Active, not recruiting
- Start
- Nov 2020
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT). Started Nov 2020; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT04404881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404881.